The FDA has approved the first 2-drug regimen of dolutegravir and lamivudine for patients with treatment-naive HIV.
“Currently, the standard of care for patients who have never been treated is a three-drug regimen. With this approval, patients who have never been treated have the option of taking a two-drug regimen in a single tablet while eliminating additional toxicity and potential drug interactions from a third drug,” Debra Birnkrant, MD, director of the FDA’s Division of Antiviral Products, said in a statement.
Sancar F. Two-Drug Regimen for HIV. JAMA. 2019;321(19):1862. doi:10.1001/jama.2019.6188
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: